A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses

Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone ML29, selected from a library of MOPV/LASV (MOP/LAS) reassortants, encodes the major antigens (nucleocapsid and glycoprotein) of LASV and the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of virology Ročník 79; číslo 22; s. 13934
Hlavní autoři: Lukashevich, Igor S, Patterson, Jean, Carrion, Ricardo, Moshkoff, Dmitry, Ticer, Anysha, Zapata, Juan, Brasky, Kathleen, Geiger, Robert, Hubbard, Gene B, Bryant, Joseph, Salvato, Maria S
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.11.2005
Témata:
Adoptive Transfer
Animals
Body Weight
Disease Models, Animal
Guinea Pigs
Lassa Fever - immunology
Lassa Fever - pathology
Lassa virus - genetics
Lassa virus - immunology
Liver - immunology
Liver - pathology
Liver - virology
Lung - immunology
Lung - pathology
Lung - virology
Mice
Mice, Inbred CBA
RNA, Viral - genetics
Spleen - immunology
Vaccines, Attenuated
Viral Load
Viral Vaccines
ISSN:0022-538X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone ML29, selected from a library of MOPV/LASV (MOP/LAS) reassortants, encodes the major antigens (nucleocapsid and glycoprotein) of LASV and the RNA polymerase and zinc-binding protein of MOPV. Replication of ML29 was attenuated in guinea pigs and nonhuman primates. In murine adoptive-transfer experiments, as little as 150 PFU of ML29 induced protective cell-mediated immunity. All strain 13 guinea pigs vaccinated with clone ML29 survived at least 70 days after LASV challenge without either disease signs or histological lesions. Rhesus macaques inoculated with clone ML29 developed primary virus-specific T cells capable of secreting gamma interferon in response to homologous MOP/LAS and heterologous MOPV and lymphocytic choriomeningitis virus. Detailed examination of two rhesus macaques infected with this MOPV/LAS reassortant revealed no histological lesions or disease signs. Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.
AbstractList Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone ML29, selected from a library of MOPV/LASV (MOP/LAS) reassortants, encodes the major antigens (nucleocapsid and glycoprotein) of LASV and the RNA polymerase and zinc-binding protein of MOPV. Replication of ML29 was attenuated in guinea pigs and nonhuman primates. In murine adoptive-transfer experiments, as little as 150 PFU of ML29 induced protective cell-mediated immunity. All strain 13 guinea pigs vaccinated with clone ML29 survived at least 70 days after LASV challenge without either disease signs or histological lesions. Rhesus macaques inoculated with clone ML29 developed primary virus-specific T cells capable of secreting gamma interferon in response to homologous MOP/LAS and heterologous MOPV and lymphocytic choriomeningitis virus. Detailed examination of two rhesus macaques infected with this MOPV/LAS reassortant revealed no histological lesions or disease signs. Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.
Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone ML29, selected from a library of MOPV/LASV (MOP/LAS) reassortants, encodes the major antigens (nucleocapsid and glycoprotein) of LASV and the RNA polymerase and zinc-binding protein of MOPV. Replication of ML29 was attenuated in guinea pigs and nonhuman primates. In murine adoptive-transfer experiments, as little as 150 PFU of ML29 induced protective cell-mediated immunity. All strain 13 guinea pigs vaccinated with clone ML29 survived at least 70 days after LASV challenge without either disease signs or histological lesions. Rhesus macaques inoculated with clone ML29 developed primary virus-specific T cells capable of secreting gamma interferon in response to homologous MOP/LAS and heterologous MOPV and lymphocytic choriomeningitis virus. Detailed examination of two rhesus macaques infected with this MOPV/LAS reassortant revealed no histological lesions or disease signs. Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone ML29, selected from a library of MOPV/LASV (MOP/LAS) reassortants, encodes the major antigens (nucleocapsid and glycoprotein) of LASV and the RNA polymerase and zinc-binding protein of MOPV. Replication of ML29 was attenuated in guinea pigs and nonhuman primates. In murine adoptive-transfer experiments, as little as 150 PFU of ML29 induced protective cell-mediated immunity. All strain 13 guinea pigs vaccinated with clone ML29 survived at least 70 days after LASV challenge without either disease signs or histological lesions. Rhesus macaques inoculated with clone ML29 developed primary virus-specific T cells capable of secreting gamma interferon in response to homologous MOP/LAS and heterologous MOPV and lymphocytic choriomeningitis virus. Detailed examination of two rhesus macaques infected with this MOPV/LAS reassortant revealed no histological lesions or disease signs. Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever.
Author Patterson, Jean
Salvato, Maria S
Lukashevich, Igor S
Ticer, Anysha
Geiger, Robert
Zapata, Juan
Hubbard, Gene B
Bryant, Joseph
Moshkoff, Dmitry
Carrion, Ricardo
Brasky, Kathleen
Author_xml – sequence: 1
  givenname: Igor S
  surname: Lukashevich
  fullname: Lukashevich, Igor S
  email: lukashev@umbi.umd.edu
  organization: Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA. lukashev@umbi.umd.edu
– sequence: 2
  givenname: Jean
  surname: Patterson
  fullname: Patterson, Jean
– sequence: 3
  givenname: Ricardo
  surname: Carrion
  fullname: Carrion, Ricardo
– sequence: 4
  givenname: Dmitry
  surname: Moshkoff
  fullname: Moshkoff, Dmitry
– sequence: 5
  givenname: Anysha
  surname: Ticer
  fullname: Ticer, Anysha
– sequence: 6
  givenname: Juan
  surname: Zapata
  fullname: Zapata, Juan
– sequence: 7
  givenname: Kathleen
  surname: Brasky
  fullname: Brasky, Kathleen
– sequence: 8
  givenname: Robert
  surname: Geiger
  fullname: Geiger, Robert
– sequence: 9
  givenname: Gene B
  surname: Hubbard
  fullname: Hubbard, Gene B
– sequence: 10
  givenname: Joseph
  surname: Bryant
  fullname: Bryant, Joseph
– sequence: 11
  givenname: Maria S
  surname: Salvato
  fullname: Salvato, Maria S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16254329$$D View this record in MEDLINE/PubMed
BookMark eNo1kEtLxDAUhbMYcR76FyS4cNea3KRJuxwGHYURNwripty2N9ChjzFpC_PvLThuzgeHj7M4a7bo-o4Yu5cilhLSx-NUxzaLAWKpMqWjOTXEIESyYCshAKJEpV9Ltg7hKITU2uhrtpQGEq0gW7HvLW_qiTgOA3UjDlTxCcuy7oi73vMDhoDc0USet1gRL87c01z2fmipG3jvLg52FX_rT1Qjn2o_Bgo37MphE-j2wg37fH762L1Eh_f96257iMrEZkNkUldQicKlRtpC6KqwzklTpVaWkFkj0SldZqqYgeDSRJKlQmYWkCoNBjbs4W_35PufkcKQt3UoqWmwo34MuUmtMlYls3h3EceipSo_-bpFf87_34BfmNdkZQ
CitedBy_id crossref_primary_10_3390_pathogens7040084
crossref_primary_10_3390_v13040703
crossref_primary_10_1016_j_antiviral_2007_11_003
crossref_primary_10_1080_10807030802235151
crossref_primary_10_1128_JVI_01948_08
crossref_primary_10_1016_j_vaccine_2008_07_057
crossref_primary_10_3390_vaccines7010011
crossref_primary_10_1128_JVI_00019_09
crossref_primary_10_1186_s12985_024_02585_7
crossref_primary_10_1080_14760584_2016_1184575
crossref_primary_10_1128_JVI_02876_06
crossref_primary_10_1371_journal_pntd_0002406
crossref_primary_10_1371_journal_pntd_0003736
crossref_primary_10_1016_j_antiviral_2011_02_012
crossref_primary_10_1038_s41541_022_00551_4
crossref_primary_10_3390_v13020214
crossref_primary_10_1038_s41426_018_0119_9
crossref_primary_10_1038_s41541_018_0049_5
crossref_primary_10_3389_fcimb_2018_00240
crossref_primary_10_1371_journal_ppat_1003212
crossref_primary_10_3390_v5010241
crossref_primary_10_1128_JVI_02925_13
crossref_primary_10_3390_biomedicines10102433
crossref_primary_10_1038_nri_2016_138
crossref_primary_10_1128_jvi_00578_24
crossref_primary_10_3390_vaccines11030635
crossref_primary_10_1016_j_coviro_2019_08_001
crossref_primary_10_1128_JVI_03035_13
crossref_primary_10_1155_2010_236528
crossref_primary_10_3390_futurepharmacol5020026
crossref_primary_10_1016_j_idc_2006_02_001
crossref_primary_10_1016_j_vaccine_2007_02_038
crossref_primary_10_3390_vaccines10101668
crossref_primary_10_1128_JVI_00307_15
crossref_primary_10_3390_v10020075
crossref_primary_10_1038_s41467_023_37050_6
crossref_primary_10_1074_jbc_M109_089425
crossref_primary_10_1128_JVI_03401_14
crossref_primary_10_1016_j_virol_2005_12_001
crossref_primary_10_1093_intimm_dxq061
crossref_primary_10_1016_j_virusres_2011_09_005
crossref_primary_10_1080_14760584_2016_1182024
crossref_primary_10_1093_infdis_jiy123
crossref_primary_10_1016_j_vaccine_2011_12_134
crossref_primary_10_1128_JVI_02230_17
crossref_primary_10_3390_pathogens8030133
crossref_primary_10_1371_journal_ppat_1000455
crossref_primary_10_1128_JVI_00236_14
crossref_primary_10_1371_journal_ppat_0020051
crossref_primary_10_12688_f1000research_16989_1
crossref_primary_10_3390_v15010146
crossref_primary_10_1016_j_virol_2016_11_001
crossref_primary_10_1128_JVI_00896_06
crossref_primary_10_1016_j_vaccine_2010_11_079
crossref_primary_10_1038_s41541_024_01012_w
crossref_primary_10_1016_j_vaccine_2017_12_046
crossref_primary_10_1128_JVI_01007_14
crossref_primary_10_1016_j_it_2025_05_006
crossref_primary_10_1371_journal_ppat_1000836
crossref_primary_10_3389_fimmu_2019_00372
crossref_primary_10_3390_v4112514
crossref_primary_10_2217_fvl_15_41
crossref_primary_10_1128_jvi_01688_22
crossref_primary_10_1016_j_antiviral_2011_07_015
crossref_primary_10_1038_srep10445
crossref_primary_10_1136_bmjgh_2018_001114
crossref_primary_10_3390_v11030293
crossref_primary_10_1586_erv_12_139
crossref_primary_10_1136_bmjgh_2018_001116
crossref_primary_10_1111_cei_13295
crossref_primary_10_1186_1743_422X_10_52
crossref_primary_10_3390_v16020266
crossref_primary_10_2217_fvl_15_1
crossref_primary_10_3390_pathogens13100909
crossref_primary_10_1007_s11262_006_0050_3
crossref_primary_10_1093_infdis_jiaf323
crossref_primary_10_1093_infdis_jit004
crossref_primary_10_1016_j_ccc_2006_03_004
crossref_primary_10_1016_j_ijid_2022_04_004
crossref_primary_10_3390_pathogens8010009
crossref_primary_10_1016_j_imlet_2019_03_008
crossref_primary_10_1073_pnas_0600652103
crossref_primary_10_1128_JVI_00560_08
crossref_primary_10_3390_v16030340
crossref_primary_10_3390_vaccines7040138
crossref_primary_10_3390_v12040386
crossref_primary_10_1038_s41541_020_00219_x
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/jvi.79.22.13934-13942.2005
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
ExternalDocumentID 16254329
Genre Research Support, U.S. Gov't, P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R21-AI52367
– fundername: NIAID NIH HHS
  grantid: R21 AI052367
– fundername: NIAID NIH HHS
  grantid: R21 AI059247
– fundername: NIAID NIH HHS
  grantid: R21 AI053619
– fundername: NIAID NIH HHS
  grantid: R21-AI059247
– fundername: PHS HHS
  grantid: R01-A52367
– fundername: NIAID NIH HHS
  grantid: R01 AI052367
– fundername: NIAID NIH HHS
  grantid: R21-AI53619
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAGFI
AAYJJ
ABPPZ
ACGFO
ACNCT
ADBBV
ADXHL
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
D0S
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
NPM
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
7X8
AAFWJ
AFPKN
ID FETCH-LOGICAL-c579t-68fbeca0f8617b04db7ff16d871c29761af34c93bf34a2f851e7eb1972aed4262
IEDL.DBID 7X8
ISICitedReferencesCount 114
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000232997500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0022-538X
IngestDate Sun Nov 09 13:01:29 EST 2025
Fri May 30 11:00:31 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c579t-68fbeca0f8617b04db7ff16d871c29761af34c93bf34a2f851e7eb1972aed4262
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://doi.org/10.1128/JVI.79.22.13934-13942.2005
PMID 16254329
PQID 68736735
PQPubID 23479
ParticipantIDs proquest_miscellaneous_68736735
pubmed_primary_16254329
PublicationCentury 2000
PublicationDate 2005-11-01
PublicationDateYYYYMMDD 2005-11-01
PublicationDate_xml – month: 11
  year: 2005
  text: 2005-11-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2005
SSID ssj0014464
Score 2.2186027
Snippet Lassa virus (LASV) and Mopeia virus (MOPV) are closely related Old World arenaviruses that can exchange genomic segments (reassort) during coinfection. Clone...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 13934
SubjectTerms Adoptive Transfer
Animals
Body Weight
Disease Models, Animal
Guinea Pigs
Lassa Fever - immunology
Lassa Fever - pathology
Lassa virus - genetics
Lassa virus - immunology
Liver - immunology
Liver - pathology
Liver - virology
Lung - immunology
Lung - pathology
Lung - virology
Mice
Mice, Inbred CBA
RNA, Viral - genetics
Spleen - immunology
Vaccines, Attenuated
Viral Load
Viral Vaccines
Title A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses
URI https://www.ncbi.nlm.nih.gov/pubmed/16254329
https://www.proquest.com/docview/68736735
Volume 79
WOSCitedRecordID wos000232997500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA7VKnjx_ajPHLxuu02ymw0IUsSiYksPKouXks0DCrpbu22h_97JPvAkHrxkLxtYZr-ZfJNJvkHoOpAqVDRIPMKV8JjywaVM5HsJrC4hEb4JfF00m-DDYRTHYtRAN_VdGHesso6JRaDWmXJ75J0w4jTkNLidfnmuZ5SrrVYNNNZQkwKRcZjm8U8NARIdVmuFg1vHleQoBOTO09tjm4s2IW2YR5kHIytUKYPfiWax4PR3_vepu2i7Ipq4VyJjDzVMuo82y9aTqwP03sMfEOiwk9dMF0A4NV5K5arsGGgsfgZOLbE1AHT8KbXByQq74-s5sHW3n4gzW70jU40H2dRMJF5OZovc5IfotX__cvfgVX0WPBVwMffCyMKflL6NgM4kPtMJt7YbasilFAG60pWWMiVoAg9JLHA0wyHEC06k0U7R_gitp1lqThBmIdFKWWMTxcD-XRkQFQGrEC6N4iRpoavaZGPAsStOyNRki3xcG62Fjkurj6el3MYYMBMwSsTpn3PP0FaprOp2SM5R04IHmwu0oZbzST67LOAB43A0-AbF8sL2
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+live+attenuated+vaccine+for+Lassa+fever+made+by+reassortment+of+Lassa+and+Mopeia+viruses&rft.jtitle=Journal+of+virology&rft.au=Lukashevich%2C+Igor+S&rft.au=Patterson%2C+Jean&rft.au=Carrion%2C+Ricardo&rft.au=Moshkoff%2C+Dmitry&rft.date=2005-11-01&rft.issn=0022-538X&rft.volume=79&rft.issue=22&rft.spage=13934&rft_id=info:doi/10.1128%2FJVI.79.22.13934-13942.2005&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon